title: Delavirdine dilemma at the FDA. Food and Drug Administration.
authors.forename: T
authors.initials: T
authors.lastname: Smart
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D020008:Delavirdine; D017277:Drug Approval; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine